

## Symptomatic Treatment in Multiple Sclerosis

Sandra Bigi, MD<sup>1</sup> and E Ann Yeh, MD<sup>2</sup>

1. Clinical Research Fellow, MS and Demyelinating Disorders Program, Hospital for Sick Children, University of Toronto, Ontario, Canada; 2. Associate Professor of Pediatrics (Neurology), University of Toronto; Director, Pediatric MS and Demyelinating Disorders Program, Director, Pediatric Neurology Training Program, Associate Scientist, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada

**Citation:** *US Neurology*, 2014; 10(2):xiii [online only]

**Erratum to:** *US Neurology*, 2013;9(1):35-40

In order to comply with the latest recommendations outlined by ICMJE the publisher would like to make the following amendments to the Disclosure section of the above-mentioned paper: No funding was received for the publication of this article.